HK1053473A1 - Inhibitors of alpha-l beta-2 mediated cell adhesion. - Google Patents

Inhibitors of alpha-l beta-2 mediated cell adhesion.

Info

Publication number
HK1053473A1
HK1053473A1 HK03105854A HK03105854A HK1053473A1 HK 1053473 A1 HK1053473 A1 HK 1053473A1 HK 03105854 A HK03105854 A HK 03105854A HK 03105854 A HK03105854 A HK 03105854A HK 1053473 A1 HK1053473 A1 HK 1053473A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
beta
alpha
cell adhesion
mediated cell
Prior art date
Application number
HK03105854A
Other languages
English (en)
Inventor
Ila Sircar
Marshall Morningstar
Paul Furth
Nicholas Smith
Bradley R Teegarden
Ronald C Griffith
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of HK1053473A1 publication Critical patent/HK1053473A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
HK03105854A 1999-10-20 2003-08-14 Inhibitors of alpha-l beta-2 mediated cell adhesion. HK1053473A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16062999P 1999-10-20 1999-10-20
US20984700P 2000-06-07 2000-06-07
PCT/US2000/029273 WO2001030781A2 (en) 1999-10-20 2000-10-19 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION

Publications (1)

Publication Number Publication Date
HK1053473A1 true HK1053473A1 (en) 2003-10-24

Family

ID=26857065

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105854A HK1053473A1 (en) 1999-10-20 2003-08-14 Inhibitors of alpha-l beta-2 mediated cell adhesion.

Country Status (16)

Country Link
EP (1) EP1307455B1 (ko)
JP (1) JP3943394B2 (ko)
KR (1) KR100496940B1 (ko)
CN (2) CN1332961C (ko)
AT (1) ATE292634T1 (ko)
AU (1) AU778757B2 (ko)
BR (1) BR0014651A (ko)
CA (1) CA2388639C (ko)
DE (1) DE60019347T2 (ko)
ES (1) ES2240201T3 (ko)
HK (1) HK1053473A1 (ko)
IL (2) IL148932A0 (ko)
MX (1) MXPA02003977A (ko)
NZ (1) NZ518369A (ko)
PT (1) PT1307455E (ko)
WO (1) WO2001030781A2 (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307455B1 (en) * 1999-10-20 2005-04-06 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha-l beta-2 mediated cell adhesion
CA2416654A1 (en) * 2000-07-21 2002-01-31 Lion Bioscience Ag Bicyclic hydantoin derivatives and combinatorial libraries thereof
US6710064B2 (en) 2000-12-01 2004-03-23 Bristol-Myers Squibb Co. Hydantoin compounds useful as anti-inflammatory agents
WO2002092606A1 (fr) * 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Derives d'imidazolidine fusionnes, leur procede de preparation et d'utilisation
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200303200A (en) * 2002-02-07 2003-09-01 Tanabe Seiyaku Co Inhibitors of α L β 2 integrin mediated cell adhesion
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1539744A4 (en) 2002-07-11 2007-06-06 Vicuron Pharm Inc N-HYDROXYAMIDE DERIVATIVES WITH ANTIBACTERIAL EFFECT
AU2003282510A1 (en) 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
EP1567487A4 (en) * 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
WO2004063181A1 (en) * 2003-01-03 2004-07-29 Genzyme Corporation Urea derivatives and their use as anti-inflammatory agents
KR20050115455A (ko) * 2003-04-22 2005-12-07 아노르메드 인코포레이티드 효능이 증강된 케모킨 수용체 결합 헤테로사이클 화합물
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
ES2434467T3 (es) * 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
CA2624488A1 (en) * 2005-10-06 2007-04-12 Novartis Ag Tetrahydro-pyrrolizinone compounds as lfa-i mediators
AU2007212191B2 (en) * 2006-02-10 2011-12-22 Janssen Pharmaceutica N.V. Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
WO2008007664A1 (fr) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Composé hétérocyclique bicycique et son utilisation
JP5485164B2 (ja) 2007-11-29 2014-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−カルボン酸アミドの誘導体
US8481750B2 (en) 2009-06-02 2013-07-09 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides
MX2011012717A (es) 2009-06-02 2011-12-14 Boehringer Ingelheim Int Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazo l-3-carboxilico.
EP2734496A1 (en) * 2011-07-22 2014-05-28 Venantius Limited Indene derivatives for use in the treatment of inflammatory bowel disease
MX362290B (es) * 2013-12-09 2019-01-10 Unichem Lab Ltd Un proceso mejorado para la preparacion de (3r,4r)-(1-bencilo-4-me tilpiperidina-3-il)-metilamina.
CN106588926B (zh) * 2016-12-28 2018-10-09 华东师范大学 一种2,7-二氮杂[3,2,1]二环辛烷及其衍生物及其合成方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739511B2 (en) * 1997-08-22 2001-10-11 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
EP1307455B1 (en) * 1999-10-20 2005-04-06 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha-l beta-2 mediated cell adhesion

Also Published As

Publication number Publication date
AU778757B2 (en) 2004-12-16
BR0014651A (pt) 2002-06-18
WO2001030781A2 (en) 2001-05-03
JP3943394B2 (ja) 2007-07-11
WO2001030781A3 (en) 2001-11-22
NZ518369A (en) 2003-09-26
IL148932A0 (en) 2002-09-12
EP1307455B1 (en) 2005-04-06
CA2388639A1 (en) 2001-05-03
ES2240201T3 (es) 2005-10-16
KR20020068523A (ko) 2002-08-27
CN1185232C (zh) 2005-01-19
KR100496940B1 (ko) 2005-06-23
JP2003512468A (ja) 2003-04-02
AU1437001A (en) 2001-05-08
CN1651431A (zh) 2005-08-10
CA2388639C (en) 2007-07-17
EP1307455A2 (en) 2003-05-07
ATE292634T1 (de) 2005-04-15
IL148932A (en) 2006-12-31
DE60019347T2 (de) 2006-03-09
CN1332961C (zh) 2007-08-22
MXPA02003977A (es) 2003-09-25
CN1382143A (zh) 2002-11-27
PT1307455E (pt) 2005-06-30
DE60019347D1 (de) 2005-05-12

Similar Documents

Publication Publication Date Title
HK1053473A1 (en) Inhibitors of alpha-l beta-2 mediated cell adhesion.
DE69831868D1 (en) Antithrombosemittel
AU4327600A (en) Aryl sulfonyls as factor xa inhibitors
IL133623A0 (en) Antithrombotic agents
MY138239A (en) Nitrogen containing heterobicycles as factor xa inhibitors
GB9914486D0 (en) Medicaments
YU69902A (sh) Novi derivati piperazina
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
AU2056197A (en) M-amidino phenyl analogs as factor xa inhibitors
YU9802A (sh) Inhibitori ćelijske adhezije
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
CA2418054A1 (en) Inhibitors of .alpha.4 mediated cell adhesion
EA200500017A1 (ru) Новые соединения
AU2054700A (en) Antithrombotic amides
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
AP2000001900A0 (en) Halogeneted amidino amino acid derivatives useful as nitric oxide synthase inhibitors.
BG104447A (en) Biphenylamidine derivatives
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof
AU2001282871A1 (en) Antithrombotic agents
MXPA04007643A (es) Inhibidores de la adhesion celular mediada por integrina alb2.
HK1046146A1 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4.
AU2002356319A1 (en) Dna minor groove binding compounds
SI1244614T1 (en) Tryptase inhibitors
PL353926A1 (en) Process for the preparation of 2-cyanopyridines

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091019